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of patients with mania associated to Bipolar Disorder assessed by change in the Young 
Mania Rating Scale (YMRS) score and Clinical Global Impression (CGI) score from 
inclusion to day 21. Quality of life and safety/tolerability were measured with the 
Euro Quality of Life 5D (EQ5D), Work Productivity and Activity Impairment, Barnes 
Akathisia Rating Scale, Simpson-Angus Scale, physical examinations, adverse events, 
change of weight and other adverse events of special interest. The efﬁ cacy analysis 
was based on the modiﬁ ed intention-to-treat population, that included all patients 
who received study medication and who had a YMRS assessment at inclusion and at 
least one YMRS valid assessment after inclusion resulting in a total of 88 patients. 
RESULTS: YMRS total score reduction in 21 days was 20.55 points (95% CI, 
22.82–18.27); P < 0.0001. CGI total score decreased in 2.41 units, (95% CI, 2.69–
2.13); P < 0.0001. The EQ5D index increased 0.21 points (95% CI, 0.16–0.27) P < 
0.0001. The EQ5D Visual Analog Scale increased 23.49% (95% CI, 16.36%–
30.61%); P < 0.0001. CONCLUSIONS: Overall results shown in this study demon-
strate an improvement in the control of patients in maniac phase of bipolar disorder 
with an increase in Quality of Life.
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OBJECTIVES: For therapeutic augmentation of impaired cholinergic transmission in 
Alzheimer Disease (AD), Acetylcholine-Esterase-inhibitors (ACHE-I; galantamine, 
donepezil, rivastigmine) are approved therapies in mild to-moderate AD. The NMDA 
receptor partial antagonist (memantine) is licensed for therapy of moderate–severe 
AD. In order to inform clinical decision-making about efﬁ cacy, safety and broader 
non-cognitive outcomes, we identiﬁ ed evidence from comparative and non-compara-
tive studies. METHODS: A comprehensive search was conducted on Medline, 
Embase, conference abstracts and the Cochrane Library aimed to identify all ran-
domised, placebo controlled trials (RCTs) reporting efﬁ cacy and/or safety outcomes 
and randomised, controlled comparative trials. In a second step, trials with drug 
dosing outside the approved European Summary of Product Characteristics were 
excluded. Eligibility of trials was assessed by two blinded reviewers; quality of trials 
were assessed by CONSORT. Meta-analyses were performed, reporting ﬁ xed and 
random effects using comparative analytical techniques. RESULTS: Fifty—eight 
studies fulﬁ lled the inclusion criteria. In 45 trials, ACHE-I were tested against placebo, 
in 9 trials against another ACHE-I. For memantine, 9 placebo-controlled trials were 
identiﬁ ed. In most trials, patients were treated between 12–30 weeks; 9 RCTs reported 
longer-term outcomes, up to 24 months. After critical appraisal, 33 studies were 
included in further analyses. Meta-analysis of effects on cognition (ADAS-cog, MMSE, 
SIB) showed superiority of at least one ACHE-I versus placebo at the 3 months, 6 
months and longer-time timepoint. Results for memantine indicated non-signiﬁ cant 
improvement at any assessed timepoint. Behavioural outcomes were less well reported 
but showed superiority versus placebo for galantamine and memantine measured by 
the Neuropsychiatric Inventory Scale. CONCLUSIONS: There is abundant evidence 
for the efﬁ cacy, safety and tolerability of ACHE-Is in the treatment of patients with 
mild to moderate AD. Data for improved behavioural functioning is limited though 
available for galantamine and memantine.
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BACKGROUND: In our age and gender speciﬁ c analyses for calendar year 2003, we 
observed an administrative prevalence rate of ADHD in Nordbaden (a region in the 
South-West of Germany with a population of >2.7 million) of 0.53%, with a peak 
among 9-year old boys at 8.43%. From 2003 to 2008, methylphenidate prescriptions 
(deﬁ ned daily doses, DDDs) in Germany increased 2.65-fold, raising concern about 
potentially inappropriate use. OBJECTIVES: To establish a longitudinal ADHD 
patient database and to assess changes of ADHD administrative prevalence rates by 
age and gender during the period from 2003 to 2008, in order to lay the foundation 
for further analyses of treatment and prescribing patterns. METHODS: The complete 
claims database of the organization of physicians registered with statutory health 
insurance [SHI] (Kassenaerztliche Vereinigung, KV) in Nordbaden/Germany was 
available for analysis, covering the total regional population enrolled in SHI (>2.2 
million). Age and gender speciﬁ c 1-year prevalence rates of ADHD were determined 
for years 2003 through 2008. RESULTS: During the 6-year period under study, the 
overall one-year ADHD prevalence rate increased from 0.53% to 0.90%. ADHD 
(hyperkinetic disorder: ICD-10, F90.0, F90.1) prevalence rates were highest in the age 
group 6–12 years (peak [2008] among nine-year-old children, 9,55%; boys, 12,31%), 
increasing continuously during the observation period (a) age group 6–12: from 
4.75% (boys, 6.91%; girls, 2.46%) to 7.62% (boys, 10.44%; girls, 4.66%); (b) age 
group 13–17: from 1.73% (boys, 2.66%; girls, 0.75%) to 3.78% (boys, 5.69%; girls, 
1.74%); adults (age >18 years): from 0.04% (males, 0.05%; females, 0.03%) to 
0.14% (males, 0.18%; females, 0.10%). CONCLUSIONS: German methylphenidate 
prescription growth outpaced the increase in ADHD diagnoses from 2003 to 2008. 
Further research seems warranted and has been initiated with regard to the underlying 
dynamics of physician group involvement, coexisting conditions, utilization patterns 
(treatment duration, intensity, switches), and regarding economic implications.
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USING DRUG DISPENSING DATA TO STUDY THE VALIDITY OF 
PARASKAVEDEKATRIAPHOBIA
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OBJECTIVES: From tales of Christian tradition to essays of 17th century physicians, 
Friday has been identiﬁ ed as a day of ill luck. Amongst all Fridays of the year however 
the one coinciding with the 13th day of the month is known to be associated with 
extreme misfortune. Therefore, the fate of persons born on Friday the 13th (F13) 
warrants investigation. We investigated the effect of being born on Friday the 13th 
on the prevalence of a) cancer; b) diabetes; c) mental health disorders; and d) sexual 
disorders. METHODS: Persons born on Friday the 13th were identiﬁ ed from a drug 
utilization database. To control for seasonal variation and time-trends, persons born 
on Friday the 6th and Friday the 20th were selected as controls. Differences in pre-
scription prevalences were analyzed using multivariate logistic regression. RESULTS: 
A total of 4202 cases and 8987 controls were identiﬁ ed. The number of cases was less 
than expected based on the number of controls (expected number 4396, P < 0.01), 
suggesting a survival disadvantage for F13 cases. Age (32.8 ± 22.6 vs. 32.7 ± 23.0) 
and gender (53.1% vs. 53.3% female) were similar. Multivariable logistic regression 
showed no increase in prescription prevalences for F13 cases (P > 0.1 for all drug 
classes). Exploratory analyses showed that F13 cases being prescribed antipsychotics 
were younger than controls (P = 0.03) and diabetic cases were more often male (P = 
0.04). CONCLUSIONS: Although attenuating effects of survivor selection bias cannot 
be ruled out, the current study found no scientiﬁ c basis for paraskavedekatriaphobia 
in relation to drug utilization. Signiﬁ cant differences in age and gender for speciﬁ c 
subgroups may be attributed to the multiple comparison issue. Results will be pre-
sented on interaction effects of Friday the 13th coinciding with full-moon (n = 154) 
and good Friday (n = 113).
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OBJECTIVES: To examine the standardized mortality ratio (SMR) in inpatients with 
schizophrenia and related psychosis. METHODS: To compare the mortality risk in 
Japanese with psychosis with that of the general population, we utilized two large 
studies, called “the JESS2000” and “the JESS2000 Follow-up Study.” In the JESS2000 
study, 2,309 psychotic patients who had been hospitalized in Japanese national mental 
hospitals as of September 1, 2000 were included. In the JESS2000 Follow-up Study, 
the JESS2000 patients were followed up and those who had died as of September 1, 
2005 were identiﬁ ed retrospectively. The expected number of deaths was calculated 
by multiplying the number of patients in each gender- and age-speciﬁ c subgroup by 
the mortality rate derived from the Japanese abridged life table and adding all of the 
ﬁ gures in each of these subgroups. The SMR was calculated by the observed number 
of deaths, identiﬁ ed in the JESS2000 Follow-up Study, divided by the expected 
number. RESULTS: Of 2309 original samples, 56.3% were male. On September 1, 
2000, the mean age (SD) was 52.0 (14.6) years. The mean duration of hospitalization 
was 10.3 (12.0) years. The mean age at onset of psychosis was 23.7 (7.9) years. The 
deaths of 204 patients were conﬁ rmed as of September 1, 2005. Of these 204 deceased 
patients, 13 committed suicide, 6 died from accidents and 148 died of natural causes. 
No information regarding cause of death for the remaining 16 patients could be 
obtained. The expected numbers of deaths in this cohort was 100.67. Therefore the 
SMR for all causes in this cohort was estimated at 2.03 or more. CONCLUSIONS: 
Our ﬁ ndings were similar to the results of the systematic review by Saha et al., which 
reported the SMR for schizophrenia as 2.58. 
MENTAL HEALTH – Cost Studies
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BUDGET IMPACT ANALYSIS OF SERTINDOLE IN THE TREATMENT OF 
SCHIZOPHRENIA IN POLAND
Walczak J, Augusty ska J, Sołtys E, Nogas G
Arcana Institute, Cracow, Poland
OBJECTIVES: To evaluate the ﬁ nancial consequences of sertindole reimbursement for 
the Polish National Health Fund (NHF) budget. METHODS: Budget impact analysis 
was performed in a 3-year time horizon from two perspectives of NHF and a patient. 
Costs of oral antipsychotic drugs and EKG test of patients treated with sertindole were 
included. Two future scenarios were estimated: 1) with reimbursement of sertindole, 
and 2) without sertindole reimbursement. Target population was estimated using 
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Polish epidemiological and statistical data, and a systematic review (proportion of 
patients treated with antipsychotic drugs who withdrew because of adverse events). 
Current and predicted market shares were assessed on the basis of present sales level 
data. RESULTS: In the ﬁ rst scenario, NHF expenditures on atypical antipsychotic 
drugs will increase by: 13 mln PLN in 2010, 20 mln PLN in 2011 and 26 mln PLN 
in 2012. In the second scenario of no sertindole reimbursement NHF expenditures on 
atypical antipsychotic drugs will increase by: 11 mln PLN in 2010, 18 mln PLN in 
2011 and 23 mln PLN in 2012. From patient’s perspective, expenditures will increase 
in 2010–2012 by 0.9 mln PLN 1.3 mln PLN and 1.7 mln respectively in scenario with 
sertindole reimbursement, while in a second scenario costs will increase in 2010–2012 
by 1.1 mln PLN, 1.6 mln PLN and 2.0 mln PLN respectively. The 2009 weighted 
average exchange rate of Polish National Bank was c1 = PLN 4.3273. CONCLU-
SIONS: Reimbursement of sertindole would result in a minor increase in Polish NHF 
expenditures. Simultaneously, it would enlarge the scope of accessible therapies for 
patients intolerant to at least one other antipsychotic agent.
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COST SAVING POTENTIAL OF GENERIC SUBSTITUTION: THE CASE OF 
ANTIDEPRESSANTS
van der Westhuizen E, Burger JR, Lubbe MS, Serfontein JHP
North-West University, Potchefstroom, South Africa
OBJECTIVES: Generic medicines are generally considerably less expensive than 
branded products and their endorsement can lead to substantial savings in costs. The 
main objective of the study was to calculate potential cost savings that can be gener-
ated by generic substitution of antidepressants within the private health care sector of 
South Africa. METHODS: Data on computerised medicine claims of patients receiving 
one or more antidepressants during three consecutive years (i.e. 2004, 2005 and 2006) 
were elicited from a South African pharmaceutical beneﬁ t management company. a 
non-experimental, quantitative, retrospective drug utilization review was conducted 
and data were analyzed using the Statistical Analysis System® programme. Potential 
cost savings deﬁ ned as the collective amount that could be saved annually by substitut-
ing the average price of innovator active substances for that of generic equivalent(s) 
were computed for criteria-eligible substances in the study population. All costs are 
expressed in $U.S. RESULTS: A total of 292,071 items (N = 5,982,869) on 273,673 
prescriptions (N = 5,213,765) at a total cost of $8,652,289.48 (N = $207,316,483.10) 
were included in the study. Generic products constituted 58.7% (n = 292,071) of all 
antidepressants claimed, at a total cost of 28.2% (N = $207,316,483.10) of all 
incurred costs. With total substitution of the average price of all criteria-eligible 
innovators, a potential saving of 9.3% (N = $8,652,289.48) of the actual antidepres-
sant cost over the study period, was calculated. CONCLUSIONS: In developing 
countries with limited health care budgets, such as South Africa, generic substances 
can be cost-saving treatment alternatives. Health care professionals, third-party 
payers, and patients all have fundamental roles to play in order to encourage greater 
use of generics. Medicine expenditure can thereby be reduced and access to scarce 
resources increased, in order to meet the pressing health care needs within South 
Africa.
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BUDGET IMPACT ANALYSIS OF AMISULPRIDE IN TREATMENT OF 
SCHIZOPHRENIA IN POLAND
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OBJECTIVES: To estimate the impact of amisulpride continued reimbursement in 
schizophrenia treatment on payer’s budget in Poland. METHODS: The analysis was 
performed in 5-year time horizon from the payer (National Health Fund, NHF) 
perspective and payer + patient perspective. Only costs of medicines were included. 
On the base of IMS Health Poland sale data for years 2005–2010 linear regression 
was conducted to predict consumption and prevalence of antipsychotics in Poland. 
Cost data of medicines were obtained from Ministry of Health and medicine portals 
in case of lack of reimbursement. One-way sensitivity analysis were performed for the 
key input parameters. RESULTS: From the payer perspective, cost of amisulpride is 
approximately c7.13 million in 2010 and c9.15 million in 2014 and it represents from 
4.62% in 2010 to 4.28% in 2014 of the total cost of schizophrenia treatment esti-
mated at approximately c154.22 million in 2010 and c213.87 million in 2014. From 
the payer + patient perspective, cost of amisulpride is approximately c7.26 million in 
2010 and c9.32 million in 2014 and it represents from 4.01% in 2010 to 3.85% of 
the total cost of schizophrenia treatment estimated at approximately c181.11 million 
in 2010 and c241.81 million in 2014. Increase of NHF and patients expenses is related 
to an increase of antipsychotics sales over a span of the next ﬁ ve years caused by 
expanding awareness of schizophrenia and the importance of treatment. CONCLU-
SIONS: Our ﬁ ndings suggest that the cost of treatment with amisulpride are at a 
reasonable level and represent a small proportion of the total costs of schizophrenia 
treatment both from the payer perspective and common payer + patient perspective. 
The declining trend in the share of amisulpride cost in total cost of schizophrenia is 
noticeable. Amisulpride is an alternative therapeutic option of schizophrenia treatment 
in Poland and its reimbursement from public funds is justiﬁ ed.
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COST IMPACT OF INITIATING PREGABALIN TREATMENT IN SWEDISH 
PATIENTS WITH GENERALIZED ANXIETY DISORDER
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OBJECTIVES: To compare the health care costs 6 months prior to and 6 months after 
initiation of pregabalin in generalized anxiety disorder (GAD) patients in Sweden. 
METHODS: This was a retrospective longitudinal database study of GAD patients from 
the South-West region of Sweden (1.5 million inhabitants). Individual patient data on 
health care visits (outpatient, inpatient, primary care), costs, mortality and diagnoses 
were included from year 2000. Data from the Swedish Prescribed Drug Register were 
included from July 1, 2005 until December 31, 2007. Patients with a GAD (ICD-10 
F41.1) diagnosis and who initiated pregabalin treatment in 2006 were included. Health 
care utilization was measured six months before and six months after pregabalin initia-
tion. Patients with 2 or more prescriptions of benzodiazepines six months prior to 
pregabalin initiation were categorized as benzodiazepine patients. Non-parametric sta-
tistical tests (Mann-Whitney) were used for the cost and resource use comparisons. 
RESULTS: A total of 149 patients met the inclusion criteria, of whom 99 used benzo-
diazepines prior to pregabalin treatment. The number of in-patient (P < 0.05) and 
primary care (P < 0.05) visits signiﬁ cantly decreased in the 6-month period following 
pregabalin initiation. There was also a statistically signiﬁ cant reduction (p = 0.0004) in 
overall health care costs from SEK 71,000 (c7,408) to SEK 45,000 (c4,695). Among 
the benzodiazepine users (n = 99), the number of in-patient visits (p = 0.0213), days in 
hospital (p = 0.0026) and primary care visits (p = 0.0121) were all statistically signiﬁ -
cantly reduced following pregabalin initiation. The reduction in total cost (from SEK 
79,000 to SEK 43,000; c8,243 to c4,486) among the users of benzodiazepines was also 
statistically signiﬁ cant (p = 0.0001). The decrease in total cost, in all patients as well as 
benzodiazepine treated, was to a large extent explained by the decrease in in-patient 
costs. CONCLUSIONS: Initiating treatment with pregabalin in GAD patients signiﬁ -
cantly reduced health care utilization and costs during the following 6 months.
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OBJECTIVES: There is accumulating evidence of sub-therapeutic second-generation 
antipsychotic (SGA) dosing for patients diagnosed with bipolar disorder, leading to 
suboptimal control of disease and higher overall treatment costs. The objectives of 
this study were to identify Medicaid bipolar patients receiving clinically effective doses 
of SGAs and compare their medical costs. METHODS: Patients with bipolar disorder 
taking an oral SGA (aripiprazole, olanzapine, quetiapine, risperidone or ziprasidone) 
were identiﬁ ed in Medicaid claims databases (2005–2008) from 8 US states. Patients 
were followed for 18 months (6-month pre-index period during which patients did 
not receive an SGA, followed by a 12-month post-index utilization period to determine 
total costs). For patients on recommended dosing, costs were compared using a gen-
eralized linear model with a gamma distribution and log-link function. Baseline 
covariates (age, gender, race, pre-index costs, Charlson co-morbidity score, and spe-
ciﬁ c psychiatric co-morbidities) were adjusted for. Ziprasidone-treated patients com-
prised the reference group. RESULTS: A total of 2446 patients met inclusion criteria, 
with 45% (N = 1102) taking clinically effective doses by day 61 of their follow-up 
period. Patients on quetiapine had the lowest percentage of effective dosing at 26% 
(N = 280/1072). Other results were aripiprazole 77% (N = 336/448), olanzapine 52% 
(N = 118/226), risperidone 50% (N = 238/474), and ziprasidone 58% (N = 130/226). 
Regression analyses indicated that mental health-related prescription costs (P < 0.01) 
and all-prescription costs (P < 0.01) were statistically signiﬁ cantly lower for the ris-
peridone group compared to the ziprasidone group. There were no signiﬁ cant differ-
ences between the groups for total mental health-related costs or total all-cause costs 
(includes prescription and medical services). CONCLUSIONS: Less than half of the 
patients in this sample were prescribed clinically recommended doses 2 months after 
their initial start. Among patients using recommended doses, while those on risperi-
done had lower prescription costs, there were no signiﬁ cant differences for total costs 
compared to patients taking ziprasidone.
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OBJECTIVES: This study investigates the health care costs of adverse events (AE) 
associated with treatment of bipolar disorder with two atypical antipsychotics (AA): 
aripiprazole (ARI) and Olanzapine (OLA). METHODS: It was performed a cost 
analysis through a markov model considering the following health states: no existence 
